PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34173810-1 2021 BACKGROUND: Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor indicated for the treatment of patients with symptomatic heart failure with reduced ejection fraction (HFrEF). Valsartan 23-32 membrane metalloendopeptidase Homo sapiens 60-70 33822031-8 2021 Data from clinical trials and real-world experience in patients with HFrEF and advanced CKD support the benefits of dual angiotensin/neprilysin inhibition across the breadth of kidney disease stages, including patients with significant renal impairment that was not reported in the pivotal PARADIGM-HF trial, and suggests a central role for the cardiac benefits of sacubitril/valsartan in nephroprotection. Valsartan 376-385 membrane metalloendopeptidase Homo sapiens 133-143 34612065-1 2021 Background Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Valsartan 22-31 membrane metalloendopeptidase Homo sapiens 71-81 34216577-3 2021 Sacubitril/valsartan (LCZ696), the representative of the first novel angiotensin receptor-neprilysin inhibitor, has been incorporated into clinical practice guidelines for improving outcomes as a milestone in patients with heart failure. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 90-100 33808232-1 2021 The angiotensin receptor/neprilysin inhibitor Sacubitril/Valsartan (Sac/Val) has been shown to be beneficial in patients suffering from heart failure with reduced ejection fraction (HFrEF). Valsartan 57-66 membrane metalloendopeptidase Homo sapiens 25-35 33032741-4 2020 Conversely, sacubitril/valsartan, combining NP degradation inhibition through neprilysin and angiotensin receptor blockade, has led to groundbreaking findings in HFrEF. Valsartan 23-32 membrane metalloendopeptidase Homo sapiens 78-88 34859070-8 2021 Sacubitril/valsartan is the first of the class of dual neprilysin and angiotensin receptor inhibitors (ARNI). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 55-65 34703936-1 2021 Background: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor, has demonstrated survival benefit and reduces heart failure hospitalization compared with enalapril in patients with heart failure and reduced ejection fraction. Valsartan 23-32 membrane metalloendopeptidase Homo sapiens 58-68 35253964-1 2022 Sacubitril/valsartan, simultaneously inhibits neprilysin and angiotensin II receptor, showed an effect in reducing blood pressure (BP). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 46-56 34273070-2 2021 More recently, sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, combining inhibition of RAAS and potentiation of the counter-regulatory natriuretic peptide system, has been consistently demonstrated to reduce mortality and HF-related hospitalization. Valsartan 26-35 membrane metalloendopeptidase Homo sapiens 75-85 35469709-3 2022 In the last years RAAS blockade has been improved by the introduction of the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) sacubitril/valsartan, that combines RAAS inhibition with the block of neprilysin, boosting the positive effects of natriuretic peptides. Valsartan 137-146 membrane metalloendopeptidase Homo sapiens 98-108 35469709-3 2022 In the last years RAAS blockade has been improved by the introduction of the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) sacubitril/valsartan, that combines RAAS inhibition with the block of neprilysin, boosting the positive effects of natriuretic peptides. Valsartan 137-146 membrane metalloendopeptidase Homo sapiens 196-206 35343479-3 2022 Sacubitril/valsartan, a combination of an angiotensin receptor blocker and a neprilysin inhibitor pro-drug, has recently represented a game changer in the scenario of treatment of HF with reduced ejection fraction. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 77-87 33989294-0 2021 Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction? Valsartan 68-77 membrane metalloendopeptidase Homo sapiens 12-22 35050813-1 2022 INTRODUCTION: Sacubitril/valsartan is the first-in-class angiotensin-receptor neprilysin inhibitor approved in 2015 for the treatment of heart failure with reduced ejection fraction (HFrEF). Valsartan 25-34 membrane metalloendopeptidase Homo sapiens 78-88 33422508-2 2021 Sacubitril/valsartan (Entresto ; LCZ696) is the first angiotensin receptor-neprilysin inhibitor (ARNI) drug approved by the US and EU for heart failure (HF) and especially recommended for hypertensive HF (HHF). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 75-85 32490351-1 2020 Background: Sacubitril/valsartan is a first-in-class angiotensin-receptor neprilysin inhibitor used to treat heart failure with reduced ejection fraction. Valsartan 23-32 membrane metalloendopeptidase Homo sapiens 74-84 33732669-1 2021 Valsartan/sacubitril is a new agent approved for the treatment of chronic heart failure in adults, with a combination of angiotensin receptor inhibitor and neprilysin inhibitor. Valsartan 0-9 membrane metalloendopeptidase Homo sapiens 156-166 33489085-8 2020 Sacubitril/valsartan concomitantly blocks the renin-angiotensin system and inhibits neprilysin, a ubiquitous enzyme responsible for the breakdown of more than 50 vasoactive peptides, including the biologically active natriuretic peptides, bradykinin, angiotensin I and II, endothelin 1, glucagon, glucagon-like peptide-1, insulin-B chain, and others. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 84-94 33148948-5 2021 Sacubitril/valsartan is the first Angiotensin receptor-neprilysin inhibitor (ARNI) to be produced and has been shown to substantially improve cardiovascular outcomes in heart failure and delay progression of kidney disease in this population. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 55-65 33459776-5 2021 Patients receiving a neprilysin inhibitor were particularly well-treated, as evidenced by lower systolic pressures, heart rates, N-terminal prohormone B-type natriuretic peptide, and greater use of cardiac devices (all P < 0.001) when compared with those not receiving sacubitril/valsartan. Valsartan 280-289 membrane metalloendopeptidase Homo sapiens 21-31 33189632-2 2021 BACKGROUND: Neprilysin inhibition results in an increase of several vasoactive peptides that may mediate the beneficial effects of sacubitril/valsartan, including ANP. Valsartan 142-151 membrane metalloendopeptidase Homo sapiens 12-22 32710603-1 2020 AIMS: Inhibition of neprilysin and angiotensin II receptor by sacubitril/valsartan (Val) (LCZ696) reduces mortality in heart failure (HF) patients compared with sole inhibition of renin-angiotensin system. Valsartan 73-82 membrane metalloendopeptidase Homo sapiens 20-30 33224383-2 2020 Although sacubitril/valsartan (SAC/VAL), a first-in-class angiotensin receptor neprilysin inhibitor, reduces the risks of death and hospitalization for patients with heart failure, its mechanism of action is not fully understood. Valsartan 20-29 membrane metalloendopeptidase Homo sapiens 79-89 32987038-7 2020 This prevents development of pharmacological treatments from various diseases in which NEP is implicated although recently a dual-acting drug sacubitril-valsartan (LCZ696) combining a NEP inhibitor and angiotensin receptor blocker has been approved for treatment of heart failure. Valsartan 153-162 membrane metalloendopeptidase Homo sapiens 87-90 32987038-7 2020 This prevents development of pharmacological treatments from various diseases in which NEP is implicated although recently a dual-acting drug sacubitril-valsartan (LCZ696) combining a NEP inhibitor and angiotensin receptor blocker has been approved for treatment of heart failure. Valsartan 153-162 membrane metalloendopeptidase Homo sapiens 184-187 33727901-2 2020 The innovative therapeutic concept provided by sacubitril-valsartan, a molecule combining angiotensin receptor blocking agent and neprilysin inhibitor has suggested the hypothesis it would have led to a reduced risk of hospitalization for HF or death from cardiovascular causes among patients with HF and preserved ejection fraction. Valsartan 58-67 membrane metalloendopeptidase Homo sapiens 130-140 33203141-13 2020 Thus, NEP/angiotensin receptor type 1 (AT1R) inhibitor sacubitril/valsartan (SAC/VAL) may increase levels of these molecules and block AT1Rs required for ACE2 endocytosis in SARS-CoV-2 infection. Valsartan 66-75 membrane metalloendopeptidase Homo sapiens 6-9 32653447-2 2020 BACKGROUND: Both the angiotensin receptor neprilysin-inhibitor sacubitril/valsartan and the sodium glucose co-transporter 2 inhibitor dapagliflozin reduced cardiovascular death and heart failure (HF) hospitalization in patients with HF with reduced ejection fraction (HFrEF). Valsartan 74-83 membrane metalloendopeptidase Homo sapiens 42-52 30776953-1 2020 Sacubitril/valsartan (Entresto ) is the first commercially available angiotensin receptor neprilysin inhibitor (ARNI) approved for use in heart failure patients with a reduced ejection fraction. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 90-100 33004114-0 2020 Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 22-32 32319309-2 2020 The angiotensin receptor II blocker - neprilysin inhibitor (ARNI), sacubitril-valsartan has an established role in treatment of patients with HF with reduced ejection fraction (HFrEF) based on the results of PARADIGM-HF trial. Valsartan 78-87 membrane metalloendopeptidase Homo sapiens 38-48 32370992-0 2020 Response to the Letter to the Editor "When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry". Valsartan 54-63 membrane metalloendopeptidase Homo sapiens 68-78 32352509-0 2020 Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan). Valsartan 90-99 membrane metalloendopeptidase Homo sapiens 13-23 31028383-9 2020 Although no effect (compared to irbesartan control) was found on kidney function, allocation to neprilysin inhibition (sacubitril/valsartan) did reduce cardiac biomarkers more than irbesartan, suggesting that this treatment might improve cardiovascular outcomes in this population. Valsartan 130-139 membrane metalloendopeptidase Homo sapiens 96-106 32336521-0 2020 When sacubitril/valsartan met neprilysin and B-type natriuretic peptide in the labyrinth of biochemistry. Valsartan 16-25 membrane metalloendopeptidase Homo sapiens 30-40 32744827-1 2020 AIMS: The angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan (LCZ696) is recommended for the treatment of patients with heart failure in New York Heart Association (NYHA) class II-III and left ventricular ejection fraction (LVEF) 35% or less. Valsartan 74-83 membrane metalloendopeptidase Homo sapiens 35-45 32848403-6 2020 In 2014, the PARADIGM-HF trial found that sacubitril-valsartan, a combination of the ARB valsartan, and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with HFrEF, reducing the relative risk of cardiovascular (CV) death or first hospitalisation with HF by 20%. Valsartan 53-62 membrane metalloendopeptidase Homo sapiens 108-118 30991886-1 2020 Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor approved for the treatment of heart failure with reduced ejection fraction (HFrEF). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 48-58 32348960-11 2020 The results thus suggest that neprilysin-mediated degradation of gastrin and cholecystokinin is physiologically relevant and may have a role in heart failure patients treated with sacubitril/valsartan. Valsartan 191-200 membrane metalloendopeptidase Homo sapiens 30-40 32995716-2 2020 The angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, demonstrated superior efficacy in reducing cardiovascular death and HF hospitalization over standard of care therapy. Valsartan 58-67 membrane metalloendopeptidase Homo sapiens 25-35 31475794-1 2019 BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. Valsartan 69-78 membrane metalloendopeptidase Homo sapiens 37-47 31392960-1 2020 BACKGROUND: In heart failure with reduced ejection fraction (HFrEF), elevated soluble neprilysin (sNEP) levels are associated with an increased risk of cardiovascular death, and its inhibition with sacubitril/valsartan has improved survival. Valsartan 209-218 membrane metalloendopeptidase Homo sapiens 86-96 32648251-4 2020 Sacubitril/valsartan, a first-in-class drug, contains a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 56-66 31521679-2 2019 BACKGROUND: Although therapy with sacubitril/valsartan, a neprilysin inhibitor, improved patients" health status (compared with enalapril) at 8 months in the PARADIGM-HF (Prospective Comparison of ARNI with ACE inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) study, the early impact of ARNI on patients" symptoms, functions, and quality of life is unknown. Valsartan 45-54 membrane metalloendopeptidase Homo sapiens 58-68 31764806-2 2019 Recently, sacubitril/valsartan-an angiotensin receptor blocker-neprilysin inhibitor-has been added in clinical practice as a standard therapy for heart failure. Valsartan 21-30 membrane metalloendopeptidase Homo sapiens 63-73 30895809-1 2019 Sacubitril/valsartan, an angiotensin receptor neprilysin inhibitor, was shown to improve outcome in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 46-56 31074791-10 2019 CONCLUSIONS: Sacubitril/valsartan combined with a DPP-4 inhibitor lead to markedly higher concentrations of intact GLP-1 than DPP-4 inhibition alone, supporting a role for both neprilysin and DPP-4 in the metabolism of GLP-1 in humans, a finding which may have therapeutic implications. Valsartan 24-33 membrane metalloendopeptidase Homo sapiens 177-187 29450561-1 2019 BACKGROUND: Sacubitril, a neprilysin inhibitor in the combination molecule sacubitril/valsartan, slows down degradation of endogenous natriuretic peptides, thereby enhancing their beneficial cardiovascular effects. Valsartan 86-95 membrane metalloendopeptidase Homo sapiens 26-36 29450561-2 2019 However, sacubitril might also promote neuronal dysfunction and cognitive impairment in patients with chronic heart failure (CHF) treated with sacubitril/valsartan, due to possible neprilysin inhibition at the level of Central Nervous System. Valsartan 154-163 membrane metalloendopeptidase Homo sapiens 181-191 30520545-1 2019 AIM: This study aimed at evaluating the effects of sacubitril/valsartan on neprilysin (NEP), and the metabolism of natriuretic peptides in heart failure (HF) and providing additional mechanistic information on the mode of action of the drug. Valsartan 62-71 membrane metalloendopeptidase Homo sapiens 75-85 30520545-1 2019 AIM: This study aimed at evaluating the effects of sacubitril/valsartan on neprilysin (NEP), and the metabolism of natriuretic peptides in heart failure (HF) and providing additional mechanistic information on the mode of action of the drug. Valsartan 62-71 membrane metalloendopeptidase Homo sapiens 87-90 30520545-4 2019 Sacubitril/valsartan led to decrease in New York Heart Association class and improvement of echocardiographic parameters, as well as a dose-dependent decrease in soluble NEP (sNEP) activity, while sNEP concentration remained unchanged. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 170-173 30520545-9 2019 CONCLUSION: Sacubitril/valsartan rapidly and strongly reduced sNEP activity, leading to an increase in levels of NEP substrates. Valsartan 23-32 membrane metalloendopeptidase Homo sapiens 63-66 30895821-1 2019 A novel combination consisting of the neprilysin inhibitor, sacubitril, and the angiotensin-receptor blocker, valsartan (belonging to the newly established class of angiotensin receptor/neprilysin inhibitors), was shown to be effective in the treatment of heart failure (HF) by improving patient clinical status, and reducing re-hospitalization rate and mortality. Valsartan 110-119 membrane metalloendopeptidase Homo sapiens 186-196 30679005-2 2019 Sacubitril/valsartan modulates the neurohormonal axis by inhibiting both angiotensin receptors and neprilysin, and improves neurohormonal balance more than blocking the RAAS alone. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 99-109 29926350-1 2019 Dual angiotensin and neprilysin inhibition using the combination drug sacubitril-valsartan has ushered in a new era in the treatment of heart failure (HF). Valsartan 81-90 membrane metalloendopeptidase Homo sapiens 21-31 30420146-1 2019 Sacubitril/valsartan represents the first of a new class of drugs able to act as a neprilysin inhibitor and as an angiotensin receptor blocker. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 83-93 30905064-2 2019 Among these, the combined angiotensin II receptor/neprilysin inhibitor (ARNI) valsartan/sacubitril has already proven highly effective in heart failure with reduced ejection fraction (HFrEF), and convincing data are available regarding the cardioprotective effects of sodium-glucose-co-transporter 2 (SGLT2) inhibitors. Valsartan 78-87 membrane metalloendopeptidase Homo sapiens 50-60 29891240-2 2019 Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitors (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and improve symptoms in patients with chronic, ambulatory, symptomatic HFrEF in a large, phase 3, multicentre, international, randomised controlled trial, PARADIGM-HF, when compared to the gold-standard angiotensin converting enzyme inhibitor, enalapril. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 60-70 30712431-1 2019 Background The angiotensin-receptor/neprilysin inhibitor ( ARNI ) sacubitril/valsartan reduces hospitalization and mortality for patients with heart failure with reduced ejection fraction. Valsartan 77-86 membrane metalloendopeptidase Homo sapiens 36-46 30281045-1 2018 Sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is the first medication to demonstrate a mortality benefit in patients with chronic heart failure and reduced ejection fraction (HFrEF) since the early 2000s. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 62-72 30761275-2 2018 A new drug class of neprilysin inhibitors as fixed-dose combination (Sacubitril/valsartan) has been introduced and is currently being investigated in children suffering from heart failure. Valsartan 80-89 membrane metalloendopeptidase Homo sapiens 20-30 29635392-1 2019 Background: Since the introduction of sacubitril/valsartan in clinical cardiology, neprilysin has become a major target for heart failure treatment. Valsartan 49-58 membrane metalloendopeptidase Homo sapiens 83-93 30347271-1 2018 BACKGROUND: Simultaneous angiotensin receptor (AT1) blockade and neprilysin inhibition with the use of sacubitril/valsartan has been recently approved to treat patients with heart failure (HF). Valsartan 114-123 membrane metalloendopeptidase Homo sapiens 65-75 30281045-2 2018 Sacubitril/valsartan simultaneously suppresses renin-angiotensin-aldosterone system activation through blockade of angiotensin II type 1 receptors and enhances the activity of vasoactive peptides including natriuretic peptides, through inhibition of neprilysin, the enzyme responsible for their degradation. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 250-260 29776559-1 2018 BACKGROUND: PARADIGM-HF demonstrated significant clinical benefits for sacubitril/valsartan (LCZ696, an angiotensin receptor neprilysin inhibitor) versus the angiotensin-converting enzyme inhibitor (ACEI) enalapril in patients with heart failure with reduced ejection fraction. Valsartan 82-91 membrane metalloendopeptidase Homo sapiens 125-135 29957605-1 2018 The FDA has approved sacubitril/valsartan, an angiotensin-receptor-neprilysin inhibitor, for the treatment of chronic symptomatic heart failure (stage C) in patients with a left ventricular ejection fraction of 35% or less. Valsartan 32-41 membrane metalloendopeptidase Homo sapiens 67-77 29746915-1 2018 BACKGROUND: Because neprilysin is involved in the degradation of amyloid-beta, there is concern that the angiotensin-neprilysin inhibitor sacubitril-valsartan could increase the risk for dementia. Valsartan 149-158 membrane metalloendopeptidase Homo sapiens 20-30 29746915-1 2018 BACKGROUND: Because neprilysin is involved in the degradation of amyloid-beta, there is concern that the angiotensin-neprilysin inhibitor sacubitril-valsartan could increase the risk for dementia. Valsartan 149-158 membrane metalloendopeptidase Homo sapiens 117-127 30122239-0 2018 Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 51-61 30122239-1 2018 OBJECTIVE: To describe the efficacy, superiority and safety profile of the first-in-class angiotensin receptor-neprilysin inhibitor "Sacubitril/Valsartan" as compared to angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blocker (ARB) in heart failure (HF) patients, reviewing data available from both clinical and pre-clinical studies. Valsartan 144-153 membrane metalloendopeptidase Homo sapiens 111-121 29754651-1 2018 BACKGROUND: Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor indicated for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction; however, its mechanism of benefit remains unclear. Valsartan 23-32 membrane metalloendopeptidase Homo sapiens 60-70 29464879-1 2018 BACKGROUND: Sacubitril/valsartan significantly reduced heart failure hospitalization and mortality in PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Valsartan 23-32 membrane metalloendopeptidase Homo sapiens 162-172 29754651-9 2018 CONCLUSIONS: Results from the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF) will help establish a mechanistic understanding of angiotensin receptor-neprilysin inhibitor therapeutic benefits and provide clinicians with clarity on how to interpret information on biomarkers during treatment (PROVE-HF ClinicalTrials.gov identifier: NCT02887183). Valsartan 129-138 membrane metalloendopeptidase Homo sapiens 248-258 29374807-0 2018 The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Valsartan 15-24 membrane metalloendopeptidase Homo sapiens 65-75 29687191-1 2018 PURPOSE OF REVIEW: Compared to enalapril, use of angiotensin-receptor blocker and neprilysin inhibitor sacubitril/valsartan to treat patients with heart failure and reduced ejection fraction (HFrEF) is associated with substantial reductions in both cardiovascular mortality and heart failure progression. Valsartan 114-123 membrane metalloendopeptidase Homo sapiens 82-92 29643067-1 2018 BACKGROUND: In PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure), heart failure treatment with sacubitril/valsartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalization compared with enalapril but resulted in more symptomatic hypotension. Valsartan 254-263 membrane metalloendopeptidase Homo sapiens 75-85 29500454-2 2018 We have recently demonstrated that sacubitril/valsartan (LCZ696), a first-in-class angiotensin receptor neprilysin inhibitor, which blocks the angiotensin II type-1 receptor and augments natriuretic peptide levels, improved peripheral insulin sensitivity in obese hypertensive patients. Valsartan 46-55 membrane metalloendopeptidase Homo sapiens 104-114 29035000-2 2018 The combined angiotensin receptor blocker-neprilysin inhibitor, sacubitril/valsartan, is a novel therapy that can increase levels of endogenous vasoactive peptides. Valsartan 75-84 membrane metalloendopeptidase Homo sapiens 42-52 29374807-1 2018 PURPOSE OF REVIEW: Sacubitril/valsartan (LCZ696) is a first-in-class, novel-acting, angiotensin receptor neprilysin inhibitor (ARNI) that provides inhibition of neprilysin and the angiotensin (AT1) receptor. Valsartan 30-39 membrane metalloendopeptidase Homo sapiens 105-115 29374807-1 2018 PURPOSE OF REVIEW: Sacubitril/valsartan (LCZ696) is a first-in-class, novel-acting, angiotensin receptor neprilysin inhibitor (ARNI) that provides inhibition of neprilysin and the angiotensin (AT1) receptor. Valsartan 30-39 membrane metalloendopeptidase Homo sapiens 161-171 28417439-2 2017 Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5-2.0, and 2.0-3.0 h, respectively. Valsartan 191-200 membrane metalloendopeptidase Homo sapiens 91-101 28527109-0 2018 Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Valsartan 52-61 membrane metalloendopeptidase Homo sapiens 101-111 29180454-1 2018 Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced ejection fraction. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 60-70 28417439-0 2017 Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Valsartan 40-49 membrane metalloendopeptidase Homo sapiens 89-99 29542073-9 2018 Angiotensin receptor-neprilysin inhibitor (ARNI) which combines a neprilysin inhibitor and ARB valsartan have a unique mode of action targeting both RAAS and the natriuretic peptide systems. Valsartan 95-104 membrane metalloendopeptidase Homo sapiens 21-31 29532764-3 2018 Recently, the Food and Drug Administration (FDA) approved a drug with brand name Entresto (Sacubitril/Valsartan or LCZ696), an angiotensin receptor neprilysin inhibitor for the use in Heart Failure with Reduced Ejection Fraction (HFrEF) patients instead of ACEI"s and ARBs. Valsartan 102-111 membrane metalloendopeptidase Homo sapiens 148-158 28527109-2 2018 Absorption of sacubitril/valsartan and conversion of sacubitril (prodrug) to sacubitrilat (neprilysin inhibitor) was rapid with maximum plasma concentrations of sacubitril, sacubitrilat, and valsartan (angiotensin receptor blocker) reaching within 0.5, 1.5-2.0, and 2.0-3.0 h, respectively. Valsartan 191-200 membrane metalloendopeptidase Homo sapiens 91-101 29286056-3 2017 Sacubitril/valsartan (LCZ-696) is a combined neprilysin inhibitor and angiotensin AT1 receptor blocker approved in recent years for the treatment of chronic heart failure with reduced ejection fraction. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 45-55 29129252-1 2017 BACKGROUND: Sacubitril/valsartan (LCZ696) is an angiotensin receptor neprilysin inhibitor approved for the treatment of adult heart failure (HF); however, the benefit of sacubitril/valsartan in pediatric HF patients is unknown. Valsartan 23-32 membrane metalloendopeptidase Homo sapiens 69-79 28024961-2 2017 Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor shown to reduce mortality and morbidity in the recently completed largest outcome trial in patients with HFrEF (PARADIGM-HF trial). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 71-81 28689178-3 2017 The angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan, simultaneously augments the natriuretic peptide system (NPS) by inhibiting the enzyme neprilysin (NEP) and inhibits the renin-angiotensin-aldosterone system (RAAS) by blocking the angiotensin II receptor. Valsartan 58-67 membrane metalloendopeptidase Homo sapiens 25-35 28689178-3 2017 The angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan, simultaneously augments the natriuretic peptide system (NPS) by inhibiting the enzyme neprilysin (NEP) and inhibits the renin-angiotensin-aldosterone system (RAAS) by blocking the angiotensin II receptor. Valsartan 58-67 membrane metalloendopeptidase Homo sapiens 155-165 28689178-3 2017 The angiotensin receptor-neprilysin inhibitor, sacubitril/valsartan, simultaneously augments the natriuretic peptide system (NPS) by inhibiting the enzyme neprilysin (NEP) and inhibits the renin-angiotensin-aldosterone system (RAAS) by blocking the angiotensin II receptor. Valsartan 58-67 membrane metalloendopeptidase Homo sapiens 167-170 28689178-12 2017 We contend that by pre-emptively inhibiting NEP, sacubitril/valsartan is inducing this surge earlier during decompensation, resulting in the better outcomes observed. Valsartan 60-69 membrane metalloendopeptidase Homo sapiens 44-47 28587583-2 2017 With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while avoiding the deleterious effect of angiotensin II receptors activation and thereby encompasses a beneficial impact of 2 important neurohormonal pathways activated in heart failure. Valsartan 105-114 membrane metalloendopeptidase Homo sapiens 45-55 28652105-0 2017 Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan. Valsartan 111-120 membrane metalloendopeptidase Homo sapiens 70-80 28652105-4 2017 The synergism from these drugs arises from the vasodilating effects of valsartan through its blockade of Ang II type 1 receptor and the action of natriuretic peptides atrial natriuretic peptide and B-type natriuretic peptide (BNP) by preventing their catabolism with neprilysin resulting in increase of cyclic guanosine monophosphate. Valsartan 71-80 membrane metalloendopeptidase Homo sapiens 267-277 28720639-1 2017 Incorporation of neprilysin inhibition into heart failure pharmacotherapy regimens has recently been recommended by U.S. guidelines, based on results from the PARADIGM-HF trial comparing sacubitril/valsartan to enalapril. Valsartan 198-207 membrane metalloendopeptidase Homo sapiens 17-27 28844335-1 2017 Sacubitril/valsartan (LCZ696), a supramolecular sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan, was recently approved in the EU and the USA for the treatment of chronic heart failure (HF) with reduced ejection fraction (HFrEF) (NYHA class II-IV). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 75-85 28844335-4 2017 Sacubitril/valsartan represents a novel pharmacological approach that acts by enhancing the NP system via inhibition of neprilysin (an enzyme that degrades NPs) and by suppressing the RAAS via AT1 receptor blockade, thereby producing more effective neurohormonal modulation than can be achieved with RAAS inhibition alone. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 120-130 28512738-1 2017 Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) inhibits angiotensin II and neprilysin, enhancing circulating vasoactive peptides. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 60-70 28512738-1 2017 Sacubitril/valsartan, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) inhibits angiotensin II and neprilysin, enhancing circulating vasoactive peptides. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 116-126 28244205-1 2017 AIMS: The PARADIGM-HF trial showed that sacubitril-valsartan, an ARB-neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF). Valsartan 51-60 membrane metalloendopeptidase Homo sapiens 69-79 28377431-7 2017 Sacubitril/valsartan is an angiotensin receptor NEP inhibitor that prevents the clinical progression of surviving patients with heart failure more effectively than enalapril, an angiotensin-converting enzyme inhibitor. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 48-51 28285069-1 2017 Sacubitril/valsartan combines a neprilysin inhibitor with an angiotensin receptor blocker. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 32-42 27324506-1 2017 BACKGROUND AND OBJECTIVES: LCZ696 (sacubitril/valsartan) is a novel angiotensin receptor neprilysin inhibitor (ARNI) that has been developed for treatment of heart failure patients with reduced ejection fraction and approved in the US, Europe, and many other countries. Valsartan 46-55 membrane metalloendopeptidase Homo sapiens 89-99 28662936-3 2017 The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan, which has been shown to benefit patients with heart failure (HF) and reduced ejection fraction, demonstrated favorable physiologic effects in a phase II HFpEF trial. Valsartan 64-73 membrane metalloendopeptidase Homo sapiens 25-35 28315356-1 2017 Sacubitril/valsartan (LCZ696) is the first angiotensin receptor neprilysin inhibitor approved to reduce cardiovascular mortality and hospitalization in patients with heart failure with reduced ejection fraction. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 64-74 28378286-6 2017 A novel drug, the angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696), which simultaneously inhibits neprilysin and blocks the angiotensin II type I receptor, was shown to have a favorable efficacy and safety profile in patients with HFrEF and has been approved for use in such patients in Europe and the USA. Valsartan 71-80 membrane metalloendopeptidase Homo sapiens 39-49 28378286-6 2017 A novel drug, the angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696), which simultaneously inhibits neprilysin and blocks the angiotensin II type I receptor, was shown to have a favorable efficacy and safety profile in patients with HFrEF and has been approved for use in such patients in Europe and the USA. Valsartan 71-80 membrane metalloendopeptidase Homo sapiens 121-131 28281174-7 2017 Neprilysin inhibition with sacubitril/valsartan offers a new therapeutic strategy with a broad range of potential therapeutic actions. Valsartan 38-47 membrane metalloendopeptidase Homo sapiens 0-10 28176581-2 2017 On page 55, the first sentence in the angiotensin receptor neprilysin inhibitor section should read: Valsartan with sacubitril is an angiotensin receptor neprilysin inhibitor that has recently been approved for use as a replacement for ACE inhibitors, to further reduce the risk of hospitalisation and death in ambulatory patients with heart failure and an ejection fraction <=35% who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and an aldersterone antagonist (Ponikowski et al 2016). Valsartan 101-110 membrane metalloendopeptidase Homo sapiens 59-69 28030431-1 2017 OBJECTIVE: The objective of this study is to evaluate the efficacy and safety of sacubitril/valsartan (LCZ696, an angiotensin receptor and neprilysin inhibitor) add-on to amlodipine compared with amlodipine monotherapy in Asian patients with systolic hypertension uncontrolled with amlodipine. Valsartan 92-101 membrane metalloendopeptidase Homo sapiens 139-149 28176581-2 2017 On page 55, the first sentence in the angiotensin receptor neprilysin inhibitor section should read: Valsartan with sacubitril is an angiotensin receptor neprilysin inhibitor that has recently been approved for use as a replacement for ACE inhibitors, to further reduce the risk of hospitalisation and death in ambulatory patients with heart failure and an ejection fraction <=35% who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and an aldersterone antagonist (Ponikowski et al 2016). Valsartan 101-110 membrane metalloendopeptidase Homo sapiens 154-164 27766748-10 2017 Recently, however, encouraging results have been obtained with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan. Valsartan 120-129 membrane metalloendopeptidase Homo sapiens 88-98 27542885-2 2017 We hypothesized that sacubitril/valsartan (LCZ696), which augments NP through neprilysin inhibition while blocking angiotensin II type-1 (AT1 )-receptors, improves insulin sensitivity, lipid mobilization, and oxidation. Valsartan 32-41 membrane metalloendopeptidase Homo sapiens 78-88 27542885-6 2017 Results confirm that sacubitril/valsartan treatment leads to a metabolic benefit in the study population and supports the relevance of neprilysin inhibition along with AT1 -receptor blockade in the regulation of human glucose and lipid metabolism. Valsartan 32-41 membrane metalloendopeptidase Homo sapiens 135-145 28060547-1 2017 INTRODUCTION: Sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor sacubitril and angiotensin II receptor blocker valsartan. Valsartan 25-34 membrane metalloendopeptidase Homo sapiens 75-85 28060547-3 2017 Areas covered: This review discusses the clinical efficacy and safety of angiotensin receptor neprilysin inhibitor sacubitril-valsartan in heart failure with reduced ejection fraction. Valsartan 126-135 membrane metalloendopeptidase Homo sapiens 94-104 28004291-3 2017 Sacubitril/valsartan (formerly known as LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) that simultaneously suppresses RAAS activation through blockade of angiotensin II type 1 receptors and enhances vasoactive peptides including NPs through inhibition of neprilysin, the enzyme responsible for their degradation. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 89-99 27868321-1 2017 AIMS: Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM-HF which compared the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan with enalapril. Valsartan 269-278 membrane metalloendopeptidase Homo sapiens 20-30 27868321-2 2017 As neprilysin is also one of many enzymes clearing amyloid-beta peptides from the brain, there is a theoretical concern about the long-term effects of sacubitril/valsartan on cognition. Valsartan 162-171 membrane metalloendopeptidase Homo sapiens 3-13 28004291-3 2017 Sacubitril/valsartan (formerly known as LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) that simultaneously suppresses RAAS activation through blockade of angiotensin II type 1 receptors and enhances vasoactive peptides including NPs through inhibition of neprilysin, the enzyme responsible for their degradation. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 285-295 27573608-1 2016 The combination of neprilysin inhibitor sacubitril with the angiotensin II receptor 1 blocker valsartan is the first agent from the angiotensin receptor neprilysin inhibitors (ARNI) class authorized for clinical use in heart failure (HF) patients with reduced ejection fraction (HFrEF). Valsartan 94-103 membrane metalloendopeptidase Homo sapiens 153-163 27719743-1 2016 OBJECTIVE: Sacubitril/valsartan (LCZ696) provides a novel therapeutic approach of neurohormonal modulation in heart failure via simultaneous inhibition of neprilysin and blockade of the angiotensin II type-1 receptor. Valsartan 22-31 membrane metalloendopeptidase Homo sapiens 155-165 27653223-0 2016 Angiotensin Neprilysin Inhibition for Patients With Heart Failure: What If Sacubitril/Valsartan Were a Treatment for Cancer? Valsartan 86-95 membrane metalloendopeptidase Homo sapiens 12-22 27803793-2 2016 Sacubitril/valsartan (previously known as LCZ696) is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor blocker (valsartan). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 95-105 28133468-3 2016 It is described as the first in class angiotensin receptor neprilysin inhibitor (ARNI) since it incorporates the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan. Valsartan 190-199 membrane metalloendopeptidase Homo sapiens 59-69 26931777-2 2016 Sacubitril/valsartan (LCZ696) is an angiotensin receptor neprilysin inhibitor (ARNI) providing simultaneous inhibition of neprilysin (neutral endopeptidase 24.11; NEP) and blockade of the angiotensin II type-1 (AT1) receptor. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 57-67 26931777-2 2016 Sacubitril/valsartan (LCZ696) is an angiotensin receptor neprilysin inhibitor (ARNI) providing simultaneous inhibition of neprilysin (neutral endopeptidase 24.11; NEP) and blockade of the angiotensin II type-1 (AT1) receptor. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 122-132 26931777-2 2016 Sacubitril/valsartan (LCZ696) is an angiotensin receptor neprilysin inhibitor (ARNI) providing simultaneous inhibition of neprilysin (neutral endopeptidase 24.11; NEP) and blockade of the angiotensin II type-1 (AT1) receptor. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 134-161 26931777-2 2016 Sacubitril/valsartan (LCZ696) is an angiotensin receptor neprilysin inhibitor (ARNI) providing simultaneous inhibition of neprilysin (neutral endopeptidase 24.11; NEP) and blockade of the angiotensin II type-1 (AT1) receptor. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 163-166 27803793-2 2016 Sacubitril/valsartan (previously known as LCZ696) is a first-in-class medicine that contains a neprilysin (NEP) inhibitor (sacubitril) and an angiotensin II (Ang-II) receptor blocker (valsartan). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 107-110 27456554-3 2016 More than one decade after spironolactone, two novel therapeutic principles have been added to the very recently released guidelines on heart failure therapy: the HCN-channel inhibitor ivabradine and the combined angiotensin and neprilysin inhibitor valsartan/sacubitril. Valsartan 250-259 membrane metalloendopeptidase Homo sapiens 229-239 27364182-1 2016 AIMS: The combined neprilysin/renin-angiotensin system (RAS) inhibitor sacubitril/valsartan reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all-cause mortality in a large outcomes trial. Valsartan 82-91 membrane metalloendopeptidase Homo sapiens 19-29 27230850-1 2016 PURPOSE: LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor, is indicated for chronic heart failure (HF) and reduced ejection fraction (HFrEF) to reduce the risk of cardiovascular death and hospitalization for HF. Valsartan 28-37 membrane metalloendopeptidase Homo sapiens 64-74 26626162-3 2016 Ivabradine and sacubitril/valsartan, which inhibit the f-channel and the angiotensin receptor and neprilysin, respectively, were recently approved by the Food and Drug Administration for HFrEF. Valsartan 26-35 membrane metalloendopeptidase Homo sapiens 98-108 27207980-0 2016 The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Valsartan 85-94 membrane metalloendopeptidase Homo sapiens 4-14 27092662-1 2016 The aim of this comprehensive review article is to emphasize on the possible exploration of a new therapeutic approach in the management of heart failure (HF) and other cardiovascular diseases: the renin-angiotensin-aldosterone system-neprilysin combination inhibitors, also called angiotensin receptor neprilysin inhibitor, valsartan/sacubitril (LCZ696). Valsartan 325-334 membrane metalloendopeptidase Homo sapiens 235-245 27438344-1 2016 IMPORTANCE: The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in cardiovascular mortality, all-cause mortality, and hospitalizations compared with enalapril. Valsartan 69-78 membrane metalloendopeptidase Homo sapiens 37-47 27324636-2 2016 The primacy of this approach has now been superseded by striking new data resulting in the approval of the combination of valsartan and sacubitril, a neprilysin inhibitor (also known as LCZ696), in 2015 for the treatment of HFrEF. Valsartan 122-131 membrane metalloendopeptidase Homo sapiens 150-160 27284124-2 2016 (1) It is described as an angiotensin receptor neprilysin inhibitor and contains the neprilysin inhibitor, sacubitril and the angiotensin II receptor antagonist, valsartan. Valsartan 162-171 membrane metalloendopeptidase Homo sapiens 47-57 27038558-5 2016 Sacubitril/valsartan combines a neprilysin inhibitor that increases levels of beneficial vasodilatory peptides with an angiotensin receptor antagonist. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 32-42 27668049-0 2016 Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure. Valsartan 21-30 membrane metalloendopeptidase Homo sapiens 69-79 26873036-1 2016 Sacubitril/valsartan is a novel, first-in-class drug, which combines a neprilysin inhibitor with an angiotensin receptor blocker. Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 71-81 26873036-3 2016 Valsartan counterbalances the increase of angiotensin II that results from neprilysin inhibition, exerting also the beneficial effects of angiotensin receptor blockers seen in previous HF trials. Valsartan 0-9 membrane metalloendopeptidase Homo sapiens 75-85 26992459-0 2016 Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. Valsartan 38-47 membrane metalloendopeptidase Homo sapiens 0-10 26992459-4 2016 This article reviews the background, current knowledge and data supporting the use of sacubitril/valsartan (Entresto( ) ), the newly FDA-approved medication that dually inhibits angiotensin and neprilysin, in the treatment of heart failure. Valsartan 97-106 membrane metalloendopeptidase Homo sapiens 194-204 26992459-12 2016 The combination of sacubitril with valsartan in a single formulation offers the benefit of concurrent blockade of the renin angiotensin aldosterone system and the inhibition of neprilysin while minimizing angioedema risk. Valsartan 35-44 membrane metalloendopeptidase Homo sapiens 177-187 26976916-3 2016 In July 2015, the US Food and Drug Administration approved the first of a new class of drugs for the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marketed by Novartis as Entresto) combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramolecular complex. Valsartan 129-138 membrane metalloendopeptidase Homo sapiens 284-294 26280447-1 2016 The aim of this MiniReview was to introduce the newly invented dual-acting drug valsartan/sacubitril (LCZ696), which combines an angiotensin receptor blocker (valsartan) with sacubitril, a specific inhibitor of the neutral endopeptidase (NEP) that degrades vasoactive peptides, including natriuretic peptides ANP and BNP, but also glucagon, enkephalins and bradykinin, among others. Valsartan 80-89 membrane metalloendopeptidase Homo sapiens 215-236 26873495-1 2016 Sacubitril/valsartan (Entresto ; LCZ696) is an orally administered supramolecular sodium salt complex of the neprilysin inhibitor prodrug sacubitril and the angiotensin receptor blocker (ARB) valsartan, which was recently approved in the US and the EU for the treatment of chronic heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). Valsartan 11-20 membrane metalloendopeptidase Homo sapiens 109-119 26280447-1 2016 The aim of this MiniReview was to introduce the newly invented dual-acting drug valsartan/sacubitril (LCZ696), which combines an angiotensin receptor blocker (valsartan) with sacubitril, a specific inhibitor of the neutral endopeptidase (NEP) that degrades vasoactive peptides, including natriuretic peptides ANP and BNP, but also glucagon, enkephalins and bradykinin, among others. Valsartan 80-89 membrane metalloendopeptidase Homo sapiens 238-241 26466607-3 2015 LCZ696 (sacubitril/valsartan) is an angiotensin-receptor neprilysin inhibitor recently approved for HFrEF, with dual actions that result in enhancement of natriuretic peptide levels and blockade of angiotensin II activities. Valsartan 19-28 membrane metalloendopeptidase Homo sapiens 57-67 26175499-0 2015 Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM. Valsartan 68-77 membrane metalloendopeptidase Homo sapiens 30-40 26557227-0 2015 Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. Valsartan 21-30 membrane metalloendopeptidase Homo sapiens 69-79 26406774-2 2015 Combining an angiotensin receptor blocker, valsartan, with sacubitril, an inhibitor of neprilysin, results in increasing levels of natriuretic peptides that counterbalance high circulating levels of neurohormones in HFrEF. Valsartan 43-52 membrane metalloendopeptidase Homo sapiens 87-97 25898846-3 2015 LCZ696 (Valsartan/sacubitril) is a first-in-class angiotensin II-receptor neprilysin inhibitor. Valsartan 8-17 membrane metalloendopeptidase Homo sapiens 74-84 26179851-0 2015 [Changing the paradigm: valsartan-inhibitor of neprilysin, a new dual-acting drug for arterial hypertension and heart failure]. Valsartan 24-33 membrane metalloendopeptidase Homo sapiens 47-57